Roche returns RET inhibitorRET inhibitor to Blueprint
24 Feb 2023
Drug ApprovalLicense out/inGene TherapyAcquisition
Roche has opted to discontinue a collaboration with Massachusetts-based Blueprint Medicines, handing back the global commercialization and development rights (excluding China) to cancer drug, Gavreto.
Gavreto is a once-daily oral targeted therapy approved by the FDA for three indications: metastatic RET fusion-positive NSCLC, advanced or metastatic RET-mutant medullary thyroid cancer, advanced or metastatic RET fusion-positive thyroid cancer. RET (or RET proto oncogene) is a gene that plays a role in cell signaling.
Roche handed Blueprint $775 million to kick off the deal in July 2020 and has since given the precision therapy company approximately $1 billion between upfront and milestone payments and from cost-sharing the commercialization and development.
According to Blueprint, Roche scrapped the deal "for strategic reasons." The transition will be made slowly. Per the deal, the termination will be effective a year from the notification date of February 22, 2023. The ex-partners will work to ensure a smooth transition process with no anticipated interruptions or changes to patient access.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.